Zacks: Analysts Set $1.25 Target Price for IVERIC bio Inc (NASDAQ:ISEE)

IVERIC bio Inc (NASDAQ:ISEE) has been given a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.

Brokers have set a 12 month consensus price target of $1.25 for the company, according to Zacks. Zacks has also given IVERIC bio an industry rank of 88 out of 256 based on the ratings given to its competitors.

Several research firms recently weighed in on ISEE. Chardan Capital restated a “hold” rating and set a $1.25 target price on shares of IVERIC bio in a report on Wednesday, September 18th. ValuEngine lowered shares of IVERIC bio from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Finally, Zacks Investment Research lowered shares of IVERIC bio from a “hold” rating to a “sell” rating in a report on Tuesday, June 4th.



Large investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC purchased a new stake in IVERIC bio during the 2nd quarter worth $5,348,000. Tamarack Advisers LP purchased a new stake in IVERIC bio during the 2nd quarter worth $3,720,000. Acadian Asset Management LLC purchased a new stake in IVERIC bio during the 2nd quarter worth $1,636,000. Renaissance Technologies LLC purchased a new stake in IVERIC bio during the 2nd quarter worth $1,604,000. Finally, Vanguard Group Inc. purchased a new stake in IVERIC bio during the 2nd quarter worth $1,476,000. Institutional investors and hedge funds own 39.67% of the company’s stock.

Shares of NASDAQ:ISEE traded down $0.02 during midday trading on Tuesday, hitting $1.11. 33,253 shares of the company’s stock traded hands, compared to its average volume of 164,585. The firm has a market capitalization of $46.14 million, a P/E ratio of -0.66 and a beta of 1.18. The firm has a fifty day moving average price of $1.14. IVERIC bio has a twelve month low of $1.02 and a twelve month high of $2.57.

IVERIC bio (NASDAQ:ISEE) last posted its earnings results on Thursday, August 1st. The company reported ($0.35) earnings per share for the quarter. On average, sell-side analysts predict that IVERIC bio will post -1.4 earnings per share for the current fiscal year.

About IVERIC bio

IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).

Read More: How to build a Fibonacci channel

Get a free copy of the Zacks research report on IVERIC bio (ISEE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.